- Home
- JNJ
as 10-29-2025 4:00pm EST
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
| Founded: | 1886 | Country: | United States |
| Employees: | N/A | City: | NEW BRUNSWICK |
| Market Cap: | 408.0B | IPO Year: | 1944 |
| Target Price: | $196.19 | AVG Volume (30 days): | 8.3M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 10.35 | EPS Growth: | 71.26 |
| 52 Week Low/High: | $140.68 - $194.48 | Next Earning Date: | 10-14-2025 |
| Revenue: | $92,149,000,000 | Revenue Growth: | 5.08% |
| Revenue Growth (this year): | 6.63% | Revenue Growth (next year): | 5.31% |
Stock Insider Trading Activity of Johnson & Johnson (JNJ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| REED JOHN C | JNJ | EVP, Innovative Medicine, R&D | Oct 17 '25 | Sell | $192.71 | 21,721 | $4,185,793.09 | 10,658 | |
| Taubert Jennifer L | JNJ | EVP, WWC. Innovative Medicine | Sep 4 '25 | Sell | $177.81 | 56,471 | $10,040,882.63 | 178,013.001 | |
| Duato Joaquin | JNJ | CEO and Chairman of the Board | Aug 22 '25 | Sell | $179.21 | 125,824 | $22,548,654.81 | 275,967 | |
| Wolk Joseph J | JNJ | Exec VP, CFO | Aug 15 '25 | Sell | $176.91 | 16,820 | $2,975,570.69 | 14,000 |
Latest Johnson & Johnson News
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
Zacks
13 hours ago
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
MT Newswires
15 hours ago
Johnson & Johnson Plans Study Comparing Imaavy With Another FcRn Blocker
PR Newswire
17 hours ago
Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
Insider Monkey
a day ago
Freedom Capital Downgrades Johnson & Johnson (JNJ) to Hold Despite Strong Q3 Results
GlobeNewswire
a day ago
Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson
Simply Wall St.
a day ago
Is Johnson & Johnson’s Share Price Justified After Recent Surge in 2025?
The Wall Street Journal
a day ago
Texas Suit Accuses Tylenol Maker of Hiding a Link to Autism
Barrons.com
2 days ago
Tylenol Is Tied to Autism, Texas Claims in Suit. Kenvue Stock Shudders.
Compare JNJ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.